.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Cantor Fitzgerald
Cerilliant
Healthtrust
US Army
Argus Health
Daiichi Sankyo
US Department of Justice
Medtronic
Merck

Generated: June 22, 2017

DrugPatentWatch Database Preview

Glipizide - Generic Drug Details

« Back to Dashboard

What are the generic sources for glipizide and what is the scope of glipizide freedom to operate?

Glipizide
is the generic ingredient in five branded drugs marketed by Sandoz, Barr Labs Inc, Unique Pharm Labs, Sun Pharm Inds Inc, Watson Labs Teva, Mylan, Aurobindo Pharma Ltd, Pfizer, Accord Hlthcare, Par Pharm, Watson Labs, Vintage Pharms Llc, Ani Pharms Inc, Apotex, Mylan Pharms Inc, Zydus Pharms Usa Inc, Epic Pharma Llc, Heritage Pharms Inc, Bristol Myers Squibb, and Teva Pharms, and is included in twenty-seven NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Glipizide has twenty-three patent family members in nineteen countries.

There are eighteen drug master file entries for glipizide. Fifty-six suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: glipizide

Tradenames:5
Patents:2
Applicants:20
NDAs:27
Drug Master File Entries: see list18
Suppliers / Packagers: see list56
Bulk Api Vendors: see list72
Clinical Trials: see list31
Patent Applications: see list5,666
Therapeutic Class:Blood Glucose Regulators
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:glipizide at DailyMed

Pharmacology for Ingredient: glipizide

Ingredient-typeSulfonylurea Compounds
Drug ClassSulfonylurea

Tentative approvals for GLIPIZIDE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe2.5MGTABLET, EXTENDED RELEASE;ORAL
► Subscribe► Subscribe10MGTABLET, EXTENDED RELEASE;ORAL
► Subscribe► Subscribe5MGTABLET, EXTENDED RELEASE;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz
GLIPIZIDE
glipizide
TABLET;ORAL074542-001Jun 20, 1995DISCNNoNo► Subscribe► Subscribe
Watson Labs Teva
GLIPIZIDE
glipizide
TABLET;ORAL074223-001Feb 27, 1995ABRXNoNo► Subscribe► Subscribe
Apotex
GLIPIZIDE
glipizide
TABLET;ORAL075795-002Jun 13, 2001ABRXNoNo► Subscribe► Subscribe
Aurobindo Pharma Ltd
GLIPIZIDE
glipizide
TABLET, EXTENDED RELEASE;ORAL206928-003May 12, 2017ABRXNoNo► Subscribe► Subscribe
Pfizer
GLUCOTROL
glipizide
TABLET;ORAL017783-002May 8, 1984ABRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: glipizide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-003Aug 10, 19995,091,190► Subscribe
Pfizer
GLUCOTROL
glipizide
TABLET;ORAL017783-002May 8, 19843,669,966► Subscribe
Pfizer
GLUCOTROL
glipizide
TABLET;ORAL017783-001May 8, 19843,669,966► Subscribe
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-002Apr 26, 19944,612,008► Subscribe
Pfizer
GLUCOTROL XL
glipizide
TABLET, EXTENDED RELEASE;ORAL020329-003Aug 10, 19995,591,454► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: glipizide

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,591,454 Method for lowering blood glucose► Subscribe
5,024,843 Oral hypoglycemic glipizide granulation► Subscribe
6,361,795 Method for lowering blood glucose► Subscribe
5,545,413 Dosage form for administering oral hypoglycemic glipizide► Subscribe
5,091,190 Delivery system for administration blood-glucose lowering drug► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: glipizide

Country Document Number Estimated Expiration
Norway303963► Subscribe
Ireland62594► Subscribe
Denmark0490991► Subscribe
Australia6417590► Subscribe
Austria94393► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Accenture
Teva
Fuji
Harvard Business School
Merck
Novartis
Mallinckrodt
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot